Results 251 to 260 of about 219,440 (288)

Different clearance of KITD816V mutation and tryptase levels after haematopoietic cell transplantation in patients with systemic mastocytosis with associated haematological neoplasm

British Journal of Haematology, EarlyView.
Summary The patterns of tryptase normalization, KITD816V clearance and establishment of donor cell chimerism were analysed in 13 patients with systemic mastocytosis and associated haematological neoplasm (AHN) after haematopoietic cell transplantation (HCT).
Christian Niederwieser, Anita Badbaran, Radwan Massoud, Nico Gagelmann, Ameya Kunte, Evgeny Klyuchnikov, Niloufar Seyedi, Silke Heidenreich, Ina Rudolph, Gaby Zeck, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis Ayuk, Nicolaus Kröger   +14 more
wiley   +1 more source

Clinical management of CMML—State of the art

British Journal of Haematology, EarlyView.
Patients with chronic myelomonocytic leukaemia (CMML) typically present with clinical feature including splenomegaly, constitutional symptoms and autoimmune phenomena, as well as with pathological blood counts and biological features in the marrow. These characteristics may influence the assignment to prognostic categories such as the CPSSmol and also ...
K. Nachtkamp, F. Schulz, N. Gattermann, U. Germing   +3 more
wiley   +1 more source

A prior status of graft‐versus‐host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation

British Journal of Haematology, EarlyView.
Summary Optimizing the effectiveness of donor lymphocyte infusion (DLI) for relapse after allogeneic stem cell transplantation (alloHSCT) has been challenging. We investigated whether the benefits of achieving full donor chimerism (FDC) and developing graft‐versus‐host disease (GVHD) after DLI are affected by a history of GVHD before DLI.
Claudia Mae Velasco, Yoshitaka Inoue, Joseph Cioccio, Kevin Rakszawski, Natthapol Songdej, Myles Nickolich, Hong Zheng, Seema Naik, Christopher Ehmann, Joseph Mierski, Brooke Silar, Caitlin Vajdic, Robert Greiner, Valerie Brown, Shin Mineishi, Hiroko Shike, Kentaro Minagawa   +16 more
wiley   +1 more source

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

British Journal of Haematology, EarlyView.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed.
Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Max J. Gordon, James D. Phelan, Jagan R. Muppidi, Atekelt Tadese, Sarah Evans, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski   +11 more
wiley   +1 more source

Low rates of endothelial cell dysfunction and transplant‐related mortality in 537 children receiving fludarabine–treosulfan conditioning for all transplant indications: A retrospective multicentre study on behalf of the UK Paediatric BMT group

British Journal of Haematology, EarlyView.
Thomas Altmann, Kanchan Rao, Ramya Hanasoge‐Nataraj, Katharine Patrick, Ben Carpenter, Rachael Hough, Anna‐Maria Ewins, Sanjay Tewari, Oana Mirci‐Danicar, Mary Slatter, Robert Wynn, Su Han Lum   +11 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

AML-388: KDM6A Mutation in AML

Clinical Lymphoma Myeloma and Leukemia, 2020
Introduction Loss of KDM6A expression has been reported as a potential drug resistance mechanism in AML. Here, we describe the clinical characteristics and treatment outcomes in our cohort of AML patients with KDM6A mutations. Methods We annotated a cohort of 293 AML patients who were treated at our center between Jan 2016 and Dec 2019.
Suresh Kumar Balasubramanian, Jay Yang, Seongho Kim, Vijendra Singh, Omar Albanyan   +4 more
openaire   +2 more sources

Azacitidine and Venetoclax in AML

New England Journal of Medicine, 2020
Comment on the previously published paper.
Sindhura Chitikela, Lalit Kumar, Ranjit Kumar Sahoo   +2 more
openaire   +6 more sources

Enasidenib and ivosidenib in AML

Minerva Medica, 2020
The isocitrate dehydrogenases enzymes, IDH1 and IDH2, catalyze the conversion of isocitrate to α-ketoglutarate (αKG) in the cell cytoplasm and mitochondria, respectively, and contribute to generating the dihydronicotinamide-adenine dinucleotide phosphate (NADPH) as reductive potential in different cellular processes.
Martelli MP, Martino G, Cardinali V, Falini B, Martinelli G, Cerchione C.   +5 more
openaire   +4 more sources

Immunotherapy of AML

2009
The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6].
Gheath Alatrash, Jeffrey J. Molldrem
openaire   +3 more sources

Reasons for treating secondary AML as de novo AML

European Journal of Haematology, 2010
AbstractIn a Danish bi‐regional registry‐based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML.
Ostgård, Lene Sofie Granfeldt, Kjeldsen, Eigil, Holm, Mette Skov, Brown, Peter De Nully, Pedersen, Bjarne Bach, Bendix, Knud, Johansen, Preben, Kristensen, Jørgen Schøler, Nørgaard, Jan Maxwell   +8 more
openaire   +5 more sources